article thumbnail

FDA rejects Provention’s type 1 diabetes drug teplizumab

pharmaphorum

The FDA indicated something was not well with Provention Bio’s filing for type 1 diabetes therapy teplizumab in April when it delayed its review. The post FDA rejects Provention’s type 1 diabetes drug teplizumab appeared first on.

article thumbnail

Provention faces delay in FDA review of diabetes prevention antibody

pharmaphorum

The FDA says it has uncovered “deficiencies” in the marketing application for Provention Bio’s much-anticipated drug teplizumab for the prevention of type 1 diabetes (T1D) that could delay its review. The post Provention faces delay in FDA review of diabetes prevention antibody appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Nutraceuticals 2025: Mapping growth, innovation, and consumer-centric trends

Express Pharma

The nutraceutical market began to gain traction around 2005-2010, growing steadily since then. Products in this category are often prescribed by practitioners, such as nephrologists for renal care or diabetologists for managing diabetes. People started understanding the importance of maintaining their health proactively.

Diabetes 105
article thumbnail

SAEM Clinical Images Series: Insidiously Contracted Hand

ALiEM - Pharm Pearls

Risk factors for the development of Dupuytren’s contracture include northern European descent, age greater than 50 years, and diabetes. Repetitive motion occupations, tobacco use, alcohol use, and diabetes are key risk factors. Nat Rev Rheumatol 2010; 6:715. Case Question: What are the risk factors for this condition?

Diabetes 152
article thumbnail

FDA sets August decision date for Provention’s type 1 diabetes drug

pharmaphorum

Shares in Provention Bio cratered last July when the FDA turned down its marketing application for type 1 diabetes therapy teplizumab. Provention is seeking approval of teplizumab as a treatment to delay clinical type 1 diabetes in at-risk individuals, hoping the drug can become the first disease-modifying therapy in these patients.

article thumbnail

Glooko adds AI to its digital diabetes tools with xbird takeover

pharmaphorum

Glooko has made a name for itself in digital health circles with its data management tools for diabetes patients, and has now added artificial intelligence capabilities with an agreement to acquire xbird. The post Glooko adds AI to its digital diabetes tools with xbird takeover appeared first on. billion deal in 2020.

article thumbnail

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

pharmaphorum

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. The post Provention finally gets FDA nod for type 1 diabetes drug teplizumab appeared first on.